Use of bevacizumab in patients with advanced or metastatic disease
CPD Previous    

Use of bevacizumab in patients with advanced or metastatic disease

Carole Farrell Nurse clinician, The Christie NHS Foundation Trust, Manchester

Over the past ten years there has been a rapid increase in new biological (targeted) anti-cancer therapies. This brings challenges for nurses to understand how such drugs work, how they are administered and the implications for patients in terms of potential side effects. Bevacizumab (Avastin®▼) is a monoclonal antibody that targets vascular endothelial growth factor. It is licensed for use in several cancers to treat patients with advanced or metastatic disease including breast, colorectal, renal, non-small cell lung and ovarian. However, there are regional variations in funding arrangements, which nurses should be aware of.

Cancer Nursing Practice. 11, 10,29-37. doi: 10.7748/cnp2012.12.11.10.29.c9474

Correspondence

carole.farrell@christie.nhs.uk

Conflict of interest

The production cost of this article was supported by Roche Products Ltd has checked this article for factual accuracy, with editorial control remaining at all times with the journal

Peer review

This article has been subject to double blind peer review